Business Context and Reporting Period
This Form 8-K filing by Lucid Diagnostics Inc. (LUCD) reports events occurring between May 1, 2024, and May 7, 2024. The company, an emerging growth company incorporated in Delaware, announced the completion of a private placement of equity securities and a change in its board of directors.
Key Financial Metrics and Capital Structure
- Capital Raised: Approximately $11.6 million in gross proceeds.
- Securities Issued: 11,634 shares of newly designated Series B-1 Convertible Preferred Stock.
- Purchase Price: $1,000 per share.
- Closing Date: May 6, 2024.
- Conversion Price: Initial price of $0.7228 per share of Common Stock (based on the 5-day trailing average VWAP as of May 1, 2024).
- Debt and Liquidity: The filing does not provide specific data on total debt, cash flow, or liquidity ratios; it focuses solely on the equity financing event.
Material Changes and Transaction Terms
The primary material change is the issuance of Series B-1 Preferred Stock, which is senior to Common Stock and pari passu with existing Series B Preferred Stock. Key terms include:
- Conversion: Convertible at the holder's option after six months, or automatically on May 6, 2026, or upon a fundamental transaction.
- Dividends: Holders receive dividends in Common Stock equal to 20% of the shares issuable upon conversion on May 6, 2025, and May 6, 2026. Dividends are accelerated upon a fundamental transaction.
- Liquidation Preference: Holders are entitled to the greater of the stated value ($1,000) plus accrued dividends, or the amount payable if converted immediately prior to liquidation.
- Ownership Limits: Conversion and dividend rights are subject to a 4.99% beneficial ownership limitation (electable up to 9.99%) and a primary market limitation tied to the 19.99% Nasdaq Market Limit.
Management Commentary, Governance, and Risks
- Board Appointment: Effective May 6, 2024, Dennis Matheis was appointed as a Class A director. He will participate in the company's long-term incentive equity plan for non-employee directors.
- Registration Rights: The company entered into a Registration Rights Agreement to file a registration statement for the resale of Common Stock issuable upon conversion.
- Risks and Contingencies: The securities were sold under Section 4(a)(2) and Rule 506 of Regulation D exemptions. They are not registered under the Securities Act and cannot be resold without registration or an exemption. The filing notes that the press release is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the impact of the $11.6 million raise on the company's current cash runway and burn rate.
- Review the full text of the Certificate of Designation (Exhibit 3.1) to understand specific adjustment mechanisms for the conversion price.
- Assess the dilution impact on existing common shareholders given the 20% dividend accruals and the initial conversion price of $0.7228.
- Confirm the status of the Registration Rights Agreement (Exhibit 10.1) to determine when the new shares will be freely tradable.
- Monitor the company's compliance with Nasdaq listing rules regarding the 19.99% market limit for future conversions.